Identification

Name
Nabilone
Accession Number
DB00486  (APRD01127)
Type
Small Molecule
Groups
Approved, Investigational
Description

Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, however it is considered to be twice as active as Δ⁹-THC. Nabilone is approved by the FDA for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments [Label].

Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two most abundant cannabinoids found naturally in the resin of the marijuana plant, both of which are pharmacologically active due to their interaction with cannabinoid receptors that are found throughout the body [5]. While both CBD and THC are used for medicinal purposes, they have different receptor activity, function, and physiological effects. If not provided in their activated form (such as through synthetic forms like Nabilone or Dronabinol), THC and CBD are obtained through conversion from their precursors, tetrahydrocannabinolic acid-A (THCA-A) and cannabidiolic acid (CBDA), through decarboxylation reactions. This can be achieved through heating, smoking, vaporization, or baking of dried unfertilized female cannabis flowers.

From a pharmacological perspective, Cannabis' diverse receptor profile explains its potential application for such a wide variety of medical conditions. Cannabis contains more than 400 different chemical compounds, of which 61 are considered cannabinoids, a class of compounds that act upon endogenous cannabinoid receptors of the body [6]. The endocannabinoid system is widely distributed throughout the central and peripheral nervous system (via the Cannabinoid Receptors CB1 and CB2) and plays a role in many physiological processes such as inflammation, cardiovascular function, learning, pain, memory, stress and emotional regulation, and the sleep/wake cycle among many others [7]. CB1 receptors are found in both the central and peripheral nervous system, and are most abundant in the hippocampus and amygdala, which are the areas of the brain responsible for short-term memory storage and emotional regulation. CB2 receptors are mainly located in the peripheral nervous system and can be found on lymphoid tissue where they are involved in regulation of immune function [8].

In Canada, the United States, the United Kingdom and Mexico, nabilone is marketed as Cesamet. It was approved in 1985 by the United States FDA for treatment of chemotherapy-induced nausea and vomiting that has not responded to conventional antiemetics. Though it was approved by the FDA in 1985, the drug only began marketing in the United States in 2006. It is also approved for use in treatment of anorexia and weight loss in patients with AIDS.

Nabilone is a racemate consisting of the (S,S) and the (R,R) isomers.

Structure
Thumb
Synonyms
  • Nabilon
  • Nabilona
  • Nabilone
  • Nabilonum
External IDs
Cpd 109514 / LY 109 514
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act NabiloneCapsule1 mgOralActavis Pharma Company2012-10-02Not applicableCanada
Act NabiloneCapsule0.5 mgOralActavis Pharma Company2012-10-02Not applicableCanada
CesametCapsule1 mgOralValeant Canada Lp Valeant Canada S.E.C.1982-12-31Not applicableCanada
CesametCapsule1 mg/1OralMeda Pharmaceuticals Ltd2010-03-01Not applicableUs
CesametCapsule0.25 mgOralValeant Canada Lp Valeant Canada S.E.C.2008-09-12Not applicableCanada
CesametCapsule0.5 mgOralValeant Canada Lp Valeant Canada S.E.C.2004-09-16Not applicableCanada
CesametCapsule1 mg/1OralValeant Pharmaceuticals North America2009-11-012017-11-16Us
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-nabiloneCapsule0.5 mgOralApotex CorporationNot applicableNot applicableCanada
Apo-nabiloneCapsule0.25 mgOralApotex CorporationNot applicableNot applicableCanada
Apo-nabiloneCapsule1 mgOralApotex CorporationNot applicableNot applicableCanada
PMS-nabiloneCapsule0.25 mgOralPharmascience IncNot applicableNot applicableCanada
PMS-nabiloneCapsule1.0 mgOralPharmascience Inc2012-03-26Not applicableCanada
PMS-nabiloneCapsule0.5 mgOralPharmascience Inc2012-03-26Not applicableCanada
Ran-nabiloneCapsule0.25 mgOralRanbaxy Inc.2012-03-27Not applicableCanada
Ran-nabiloneCapsule1 mgOralRanbaxy Inc.2012-03-27Not applicableCanada
Ran-nabiloneCapsule0.5 mgOralRanbaxy Inc.2012-03-27Not applicableCanada
Teva-nabiloneCapsule0.5 mgOralTeva2012-05-23Not applicableCanada
International/Other Brands
Cesamet / Nabilone (Meda)
Categories
UNII
2N4O9L084N
CAS number
51022-71-0
Weight
Average: 372.5408
Monoisotopic: 372.266445018
Chemical Formula
C24H36O3
InChI Key
GECBBEABIDMGGL-RTBURBONSA-N
InChI
InChI=1S/C24H36O3/c1-6-7-8-9-12-23(2,3)16-13-20(26)22-18-15-17(25)10-11-19(18)24(4,5)27-21(22)14-16/h13-14,18-19,26H,6-12,15H2,1-5H3/t18-,19-/m1/s1
IUPAC Name
(6aR,10aR)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-6H,6aH,7H,8H,9H,10H,10aH-benzo[c]isochromen-9-one
SMILES
[H][C@@]12CC(=O)CC[C@@]1([H])C(C)(C)OC1=CC(=CC(O)=C21)C(C)(C)CCCCCC

Pharmacology

Indication

Nabilone is indicated for the treatment of the nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. This restriction is required because a substantial proportion of any group of patients treated with Nabilone can be expected to experience disturbing psychotomimetic reactions not observed with other antiemetic agents.

Associated Conditions
Pharmacodynamics

Nabilone is a cannabinoid with therapeutic uses. It is an analog of dronabinol (also known as tetrahydrocannabinol or THC), the psychoactive ingredient in cannabis. Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, however it is considered to be twice as active as Δ⁹-THC.

Mechanism of action

Nabilone is an orally active synthetic cannabinoid which, like other cannabinoids, has complex effects on the central nervous system (CNS). It has been suggested that the antiemetic effect of nabilone is caused by interaction with the cannabinoid receptor system, i.e., the CB (1) receptor, which is a component of the endocannabinoid system of the body.

The endocannabinoid system is widely distributed throughout the central and peripheral nervous system (via the Cannabinoid Receptors CB1 and CB2) and plays a role in many physiological processes such as inflammation, cardiovascular function, learning, pain, memory, stress and emotional regulation, and the sleep/wake cycle among many others [7]. CB1 receptors are found in both the central and peripheral nervous system, and are most abundant in the hippocampus and amygdala, which are the areas of the brain responsible for short-term memory storage and emotional regulation. CB2 receptors are mainly located in the peripheral nervous system and can be found on lymphoid tissue where they are involved in regulation of immune function [8].

TargetActionsOrganism
ACannabinoid receptor 2
partial agonist
Human
ACannabinoid receptor 1
partial agonist
Human
Absorption

Nabilone appears to be completely absorbed from the human gastrointestinal tract when administered orally. Following oral administration of a 2 mg dose of radiolabeled nabilone, peak plasma concentrations of approximately 2 ng/mL nabilone and 10 ng equivalents/mL total radioactivity are achieved within 2.0 hours.

Volume of distribution

The apparent volume of distribution of nabilone is about 12.5 L/kg.

Protein binding
Not Available
Metabolism

Hepatic. Two metabolic pathways have been suggested. The major pathway probably involves the direct oxidation of Nabilone to produce hydroxylic and carboxylic analogues. These compounds are thought to account for the remaining plasma radioactivity when carbinol metabolites have been extracted.

Route of elimination

The route and rate of the elimination of nabilone and its metabolites are similar to those observed with other cannabinoids, including delta-9-THC (dronabinol). When nabilone is administered intravenously, the drug and its metabolites are eliminated mainly in the feces (approximately 67%) and to a lesser extent in the urine (approximately 22%) within 7 days. Of the 67% recovered from the feces, 5% corresponded to the parent compound and 16% to its carbinol metabolite. Following oral administration about 60% of nabilone and its metabolites were recovered in the feces and about 24% in urine. Therefore, it appears that the major excretory pathway is the biliary system.

Half life

The plasma half-life (T1/2) values for nabilone and total radioactivity of identified and unidentified metabolites are about 2 and 35 hours, respectively.

Clearance
Not Available
Toxicity

Symptoms of overdose include difficulty in breathing, hallucinations, mental changes (severe), nervousness or anxiety (severe). Monkeys treated with Nabilone at doses as high as 2mg/kg/day for a year experienced no significant adverse events. This result contrasts with the finding in a planned 1-year dog study that was prematurely terminated because of deaths associated with convulsions in dogs receiving as little as 0.5mg/kg/day. The earliest deaths, however, occurred at 56 days in dogs receiving 2mg/kg/day. The unusual vulnerability of the dog is not understood; it is hypothesised, however, that the explanation lies in the fact that the dog differs markedly from other species (including humans) in its metabolism of Nabilone.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleNabilone may increase the central nervous system depressant (CNS depressant) activities of 7-Nitroindazole.Experimental
AcebutololThe risk or severity of adverse effects can be increased when Nabilone is combined with Acebutolol.Approved, Investigational
AceclofenacThe metabolism of Aceclofenac can be decreased when combined with Nabilone.Approved, Investigational
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Nabilone.Approved, Investigational
AcepromazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Acepromazine.Approved, Vet Approved
AceprometazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Aceprometazine.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Nabilone.Approved
Acetyl sulfisoxazoleThe metabolism of Acetyl sulfisoxazole can be decreased when combined with Nabilone.Approved, Vet Approved
Acetylsalicylic acidThe metabolism of Acetylsalicylic acid can be decreased when combined with Nabilone.Approved, Vet Approved
AclidiniumAclidinium may increase the tachycardic activities of Nabilone.Approved
AdipiplonNabilone may increase the central nervous system depressant (CNS depressant) activities of Adipiplon.Investigational
AgomelatineNabilone may increase the central nervous system depressant (CNS depressant) activities of Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Nabilone is combined with Alaproclate.Experimental
AlcuroniumAlcuronium may increase the tachycardic activities of Nabilone.Experimental
AldesleukinThe risk or severity of adverse effects can be increased when Nabilone is combined with Aldesleukin.Approved
AlfaxaloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Alfaxalone.Vet Approved
AlfentanilNabilone may increase the central nervous system depressant (CNS depressant) activities of Alfentanil.Approved, Illicit
AliskirenThe risk or severity of adverse effects can be increased when Nabilone is combined with Aliskiren.Approved, Investigational
AllopregnanoloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Allopregnanolone.Investigational
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Nabilone.Approved, Investigational
AlosetronThe metabolism of Alosetron can be decreased when combined with Nabilone.Approved, Withdrawn
AlphacetylmethadolNabilone may increase the central nervous system depressant (CNS depressant) activities of Alphacetylmethadol.Experimental, Illicit
AlphaprodineNabilone may increase the central nervous system depressant (CNS depressant) activities of Alphaprodine.Illicit
AlprazolamNabilone may increase the central nervous system depressant (CNS depressant) activities of Alprazolam.Approved, Illicit, Investigational
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Nabilone.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Nabilone is combined with Amiloride.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Nabilone.Approved, Withdrawn
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Nabilone.Approved, Investigational
AmisulprideNabilone may increase the central nervous system depressant (CNS depressant) activities of Amisulpride.Approved, Investigational
AmitriptylineNabilone may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Nabilone is combined with Amlodipine.Approved
AmobarbitalNabilone may increase the central nervous system depressant (CNS depressant) activities of Amobarbital.Approved, Illicit
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Nabilone.Approved, Investigational
AmodiaquineThe metabolism of Amodiaquine can be decreased when combined with Nabilone.Approved, Investigational
AmoxapineNabilone may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.Approved
AmperozideNabilone may increase the central nervous system depressant (CNS depressant) activities of Amperozide.Experimental
AmphetamineNabilone may increase the tachycardic activities of Amphetamine.Approved, Illicit, Investigational
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Nabilone.Approved, Investigational
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Nabilone.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Nabilone is combined with Amyl Nitrite.Approved
Anisotropine MethylbromideAnisotropine Methylbromide may increase the tachycardic activities of Nabilone.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Nabilone.Approved, Investigational
ApalutamideThe metabolism of Apalutamide can be decreased when combined with Nabilone.Approved, Investigational
ApixabanThe metabolism of Apixaban can be decreased when combined with Nabilone.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Nabilone.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Nabilone is combined with Apraclonidine.Approved
Arachidonic AcidThe metabolism of Arachidonic Acid can be decreased when combined with Nabilone.Experimental
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Nabilone.Approved, Investigational
AripiprazoleNabilone may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Nabilone.Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Nabilone.Approved, Investigational
ArtemetherThe metabolism of Artemether can be decreased when combined with Nabilone.Approved
ArticaineNabilone may increase the central nervous system depressant (CNS depressant) activities of Articaine.Approved
AsenapineNabilone may increase the central nervous system depressant (CNS depressant) activities of Asenapine.Approved
AsunaprevirThe serum concentration of Asunaprevir can be increased when it is combined with Nabilone.Approved, Investigational, Withdrawn
AtazanavirThe metabolism of Atazanavir can be decreased when combined with Nabilone.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Nabilone is combined with Atenolol.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Nabilone is combined with Atorvastatin.Approved
AtracuriumAtracurium may increase the tachycardic activities of Nabilone.Approved, Experimental, Investigational
Atracurium besylateAtracurium besylate may increase the tachycardic activities of Nabilone.Approved
AtropineAtropine may increase the tachycardic activities of Nabilone.Approved, Vet Approved
AvatrombopagThe metabolism of Avatrombopag can be decreased when combined with Nabilone.Approved, Investigational
AzaperoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Azaperone.Investigational, Vet Approved
AzelastineNabilone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Nabilone is combined with Azilsartan medoxomil.Approved, Investigational
BaclofenNabilone may increase the central nervous system depressant (CNS depressant) activities of Baclofen.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Nabilone.Experimental
BarbitalNabilone may increase the central nervous system depressant (CNS depressant) activities of Barbital.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Nabilone.Approved
BenactyzineBenactyzine may increase the tachycardic activities of Nabilone.Withdrawn
BenazeprilThe risk or severity of adverse effects can be increased when Nabilone is combined with Benazepril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Nabilone is combined with Bendroflumethiazide.Approved
BenperidolNabilone may increase the central nervous system depressant (CNS depressant) activities of Benperidol.Approved, Investigational
BenzatropineBenzatropine may increase the tachycardic activities of Nabilone.Approved
BenzocaineNabilone may increase the central nervous system depressant (CNS depressant) activities of Benzocaine.Approved, Investigational
BenzphetamineNabilone may increase the tachycardic activities of Benzphetamine.Approved, Illicit
Benzyl alcoholNabilone may increase the central nervous system depressant (CNS depressant) activities of Benzyl alcohol.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Nabilone.Approved, Withdrawn
BeraprostThe metabolism of Beraprost can be decreased when combined with Nabilone.Investigational
BetaxololThe risk or severity of adverse effects can be increased when Nabilone is combined with Betaxolol.Approved, Investigational
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Nabilone.Approved, Investigational
BioallethrinThe metabolism of Bioallethrin can be decreased when combined with Nabilone.Approved, Experimental
BiperidenBiperiden may increase the tachycardic activities of Nabilone.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Nabilone is combined with Bisoprolol.Approved
BornaprineBornaprine may increase the tachycardic activities of Nabilone.Experimental
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Nabilone.Approved, Investigational
BosentanThe serum concentration of Bosentan can be increased when it is combined with Nabilone.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Nabilone.Approved
BretyliumThe risk or severity of adverse effects can be increased when Nabilone is combined with Bretylium.Approved
BrexpiprazoleNabilone may increase the central nervous system depressant (CNS depressant) activities of Brexpiprazole.Approved, Investigational
BrigatinibThe metabolism of Brigatinib can be decreased when combined with Nabilone.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Nabilone.Approved
BrivaracetamThe metabolism of Brivaracetam can be decreased when combined with Nabilone.Approved, Investigational
BromazepamNabilone may increase the central nervous system depressant (CNS depressant) activities of Bromazepam.Approved, Illicit, Investigational
BromisovalNabilone may increase the central nervous system depressant (CNS depressant) activities of Bromisoval.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Nabilone.Approved, Investigational
BromperidolNabilone may increase the central nervous system depressant (CNS depressant) activities of Bromperidol.Approved, Investigational
BrompheniramineNabilone may increase the central nervous system depressant (CNS depressant) activities of Brompheniramine.Approved
BrotizolamNabilone may increase the central nervous system depressant (CNS depressant) activities of Brotizolam.Approved, Investigational, Withdrawn
BucindololNabilone may increase the tachycardic activities of Bucindolol.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Nabilone is combined with Bumetanide.Approved
BupivacaineNabilone may increase the central nervous system depressant (CNS depressant) activities of Bupivacaine.Approved, Investigational
BuprenorphineNabilone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Bupropion can be decreased when combined with Nabilone.Approved
BuspironeNabilone may increase the central nervous system depressant (CNS depressant) activities of Buspirone.Approved, Investigational
ButabarbitalNabilone may increase the central nervous system depressant (CNS depressant) activities of Butabarbital.Approved, Illicit
ButacaineNabilone may increase the central nervous system depressant (CNS depressant) activities of Butacaine.Vet Approved
ButalbitalNabilone may increase the central nervous system depressant (CNS depressant) activities of Butalbital.Approved, Illicit
ButambenNabilone may increase the central nervous system depressant (CNS depressant) activities of Butamben.Approved, Withdrawn
ButethalNabilone may increase the central nervous system depressant (CNS depressant) activities of Butethal.Approved, Illicit
ButorphanolNabilone may increase the central nervous system depressant (CNS depressant) activities of Butorphanol.Approved, Illicit, Vet Approved
ButylscopolamineButylscopolamine may increase the tachycardic activities of Nabilone.Approved, Investigational, Vet Approved
CabazitaxelThe metabolism of Cabazitaxel can be decreased when combined with Nabilone.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Nabilone.Approved
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Nabilone.Approved, Investigational
CaffeineThe metabolism of Caffeine can be decreased when combined with Nabilone.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Nabilone is combined with Canagliflozin.Approved
CandesartanThe metabolism of Candesartan can be decreased when combined with Nabilone.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Nabilone is combined with Candesartan cilexetil.Approved
CanertinibNabilone may increase the central nervous system depressant (CNS depressant) activities of Canertinib.Investigational
CannabidiolThe metabolism of Cannabidiol can be decreased when combined with Nabilone.Approved, Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Nabilone is combined with Captopril.Approved
CarbamazepineNabilone may increase the central nervous system depressant (CNS depressant) activities of Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Nabilone.Approved, Investigational
CarbinoxamineNabilone may increase the central nervous system depressant (CNS depressant) activities of Carbinoxamine.Approved
CarfentanilNabilone may increase the central nervous system depressant (CNS depressant) activities of Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolNabilone may increase the central nervous system depressant (CNS depressant) activities of Carisoprodol.Approved
CarteololThe risk or severity of adverse effects can be increased when Nabilone is combined with Carteolol.Approved
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Nabilone.Approved, Investigational
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Nabilone.Approved, Investigational
CeliprololNabilone may increase the tachycardic activities of Celiprolol.Approved, Investigational
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Nabilone.Approved, Withdrawn
CetirizineNabilone may increase the central nervous system depressant (CNS depressant) activities of Cetirizine.Approved
Chloral hydrateNabilone may increase the central nervous system depressant (CNS depressant) activities of Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideNabilone may increase the central nervous system depressant (CNS depressant) activities of Chlordiazepoxide.Approved, Illicit, Investigational
ChlormezanoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineNabilone may increase the central nervous system depressant (CNS depressant) activities of Chloroprocaine.Approved
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Nabilone.Approved, Investigational, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Nabilone is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineNabilone may increase the central nervous system depressant (CNS depressant) activities of Chlorphenamine.Approved
ChlorphenoxamineChlorphenoxamine may increase the tachycardic activities of Nabilone.Withdrawn
ChlorphentermineNabilone may increase the tachycardic activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.Approved, Investigational, Vet Approved
ChlorpropamideThe metabolism of Chlorpropamide can be decreased when combined with Nabilone.Approved, Investigational
ChlorprothixeneNabilone may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.Approved, Investigational, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Nabilone is combined with Chlorthalidone.Approved
ChlorzoxazoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Chlorzoxazone.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Nabilone is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Nabilone.Approved, Investigational
CinchocaineNabilone may increase the central nervous system depressant (CNS depressant) activities of Cinchocaine.Approved, Vet Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Nabilone.Approved, Investigational
CisaprideThe metabolism of Cisapride can be decreased when combined with Nabilone.Approved, Investigational, Withdrawn
CitalopramThe risk or severity of adverse effects can be increased when Nabilone is combined with Citalopram.Approved
ClemastineNabilone may increase the central nervous system depressant (CNS depressant) activities of Clemastine.Approved, Investigational
ClenbuterolNabilone may increase the tachycardic activities of Clenbuterol.Approved, Investigational, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Nabilone is combined with Clevidipine.Approved, Investigational
ClidiniumNabilone may increase the central nervous system depressant (CNS depressant) activities of Clidinium.Approved
ClobazamNabilone may increase the central nervous system depressant (CNS depressant) activities of Clobazam.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Nabilone.Approved, Investigational
clomethiazoleNabilone may increase the central nervous system depressant (CNS depressant) activities of clomethiazole.Investigational
ClomipramineNabilone may increase the central nervous system depressant (CNS depressant) activities of Clomipramine.Approved, Investigational, Vet Approved
ClonazepamNabilone may increase the central nervous system depressant (CNS depressant) activities of Clonazepam.Approved, Illicit
ClonidineNabilone may increase the central nervous system depressant (CNS depressant) activities of Clonidine.Approved
ClopenthixolNabilone may increase the central nervous system depressant (CNS depressant) activities of Clopenthixol.Experimental
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Nabilone.Approved
ClorazepateNabilone may increase the central nervous system depressant (CNS depressant) activities of Clorazepate.Approved, Illicit
ClothiapineNabilone may increase the central nervous system depressant (CNS depressant) activities of Clothiapine.Experimental
ClozapineNabilone may increase the central nervous system depressant (CNS depressant) activities of Clozapine.Approved
CocaineNabilone may increase the central nervous system depressant (CNS depressant) activities of Cocaine.Approved, Illicit
CodeineNabilone may increase the central nervous system depressant (CNS depressant) activities of Codeine.Approved, Illicit
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Nabilone.Approved, Investigational
CyclizineNabilone may increase the central nervous system depressant (CNS depressant) activities of Cyclizine.Approved
CyclobenzaprineNabilone may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.Approved
CyclopentolateCyclopentolate may increase the tachycardic activities of Nabilone.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Nabilone.Approved, Investigational
CyclopropaneNabilone may increase the central nervous system depressant (CNS depressant) activities of Cyclopropane.Experimental
CyproheptadineNabilone may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.Approved
DabrafenibThe metabolism of Dabrafenib can be decreased when combined with Nabilone.Approved, Investigational
DantroleneNabilone may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.Approved, Investigational
DapagliflozinThe risk or severity of adverse effects can be increased when Nabilone is combined with Dapagliflozin.Approved
DapiprazoleNabilone may increase the central nervous system depressant (CNS depressant) activities of Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Nabilone is combined with Dapoxetine.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Nabilone.Approved, Investigational
DarifenacinDarifenacin may increase the tachycardic activities of Nabilone.Approved, Investigational
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Nabilone.Approved
DeramciclaneNabilone may increase the central nervous system depressant (CNS depressant) activities of Deramciclane.Investigational
DesfluraneNabilone may increase the central nervous system depressant (CNS depressant) activities of Desflurane.Approved
DesipramineNabilone may increase the central nervous system depressant (CNS depressant) activities of Desipramine.Approved, Investigational
DesloratadineNabilone may increase the central nervous system depressant (CNS depressant) activities of Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Nabilone is combined with Desvenlafaxine.Approved, Investigational
DetomidineNabilone may increase the central nervous system depressant (CNS depressant) activities of Detomidine.Vet Approved
DexbrompheniramineNabilone may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine.Approved
DexetimideDexetimide may increase the tachycardic activities of Nabilone.Withdrawn
DexmedetomidineNabilone may increase the central nervous system depressant (CNS depressant) activities of Dexmedetomidine.Approved, Vet Approved
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Nabilone.Approved
DextromoramideNabilone may increase the central nervous system depressant (CNS depressant) activities of Dextromoramide.Experimental, Illicit
DextropropoxypheneNabilone may increase the central nervous system depressant (CNS depressant) activities of Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineNabilone may increase the central nervous system depressant (CNS depressant) activities of Dezocine.Approved, Investigational
DiazepamNabilone may increase the central nervous system depressant (CNS depressant) activities of Diazepam.Approved, Illicit, Investigational, Vet Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Nabilone.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Nabilone is combined with Diclofenamide.Approved, Investigational
DicoumarolThe metabolism of Dicoumarol can be decreased when combined with Nabilone.Approved
DicyclomineDicyclomine may increase the tachycardic activities of Nabilone.Approved
Diethyl etherNabilone may increase the central nervous system depressant (CNS depressant) activities of Diethyl ether.Experimental
DifenoxinNabilone may increase the central nervous system depressant (CNS depressant) activities of Difenoxin.Approved, Illicit
DihydrocodeineNabilone may increase the central nervous system depressant (CNS depressant) activities of Dihydrocodeine.Approved, Illicit
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Nabilone.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Nabilone.Approved, Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Nabilone.Experimental
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Nabilone.Approved, Investigational
DihydroetorphineNabilone may increase the central nervous system depressant (CNS depressant) activities of Dihydroetorphine.Experimental, Illicit
DihydromorphineNabilone may increase the central nervous system depressant (CNS depressant) activities of Dihydromorphine.Experimental, Illicit
DiltiazemThe risk or severity of adverse effects can be increased when Nabilone is combined with Diltiazem.Approved, Investigational
DimenhydrinateNabilone may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Nabilone is combined with Dinutuximab.Approved, Investigational
DiphenhydramineNabilone may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine.Approved, Investigational
DiphenoxylateNabilone may increase the central nervous system depressant (CNS depressant) activities of Diphenoxylate.Approved, Illicit
DipyridamoleThe risk or severity of adverse effects can be increased when Nabilone is combined with Dipyridamole.Approved
DixyrazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Dixyrazine.Experimental
DobutamineNabilone may increase the tachycardic activities of Dobutamine.Approved
DoconexentThe metabolism of Doconexent can be decreased when combined with Nabilone.Approved, Investigational
DolasetronThe metabolism of Dolasetron can be decreased when combined with Nabilone.Approved, Investigational
DomperidoneThe metabolism of Domperidone can be decreased when combined with Nabilone.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Nabilone.Approved
DopamineNabilone may increase the tachycardic activities of Dopamine.Approved
DoramectinNabilone may increase the central nervous system depressant (CNS depressant) activities of Doramectin.Vet Approved
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Nabilone.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Nabilone is combined with Doxazosin.Approved
DoxepinNabilone may increase the central nervous system depressant (CNS depressant) activities of Doxepin.Approved, Investigational
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Nabilone.Approved, Vet Approved
DPDPENabilone may increase the central nervous system depressant (CNS depressant) activities of DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Nabilone.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Nabilone.Approved, Vet Approved
DrotebanolNabilone may increase the central nervous system depressant (CNS depressant) activities of Drotebanol.Experimental, Illicit
DuloxetineNabilone may increase the orthostatic hypotensive activities of Duloxetine.Approved
DyclonineNabilone may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.Approved
EcgonineNabilone may increase the central nervous system depressant (CNS depressant) activities of Ecgonine.Experimental, Illicit
EcopipamNabilone may increase the central nervous system depressant (CNS depressant) activities of Ecopipam.Investigational
EfavirenzNabilone may increase the central nervous system depressant (CNS depressant) activities of Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Nabilone.Approved, Investigational
EletriptanThe metabolism of Eletriptan can be decreased when combined with Nabilone.Approved, Investigational
EltanoloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Eltanolone.Investigational
EltrombopagThe metabolism of Eltrombopag can be decreased when combined with Nabilone.Approved
EmeproniumEmepronium may increase the tachycardic activities of Nabilone.Experimental
EmpagliflozinThe risk or severity of adverse effects can be increased when Nabilone is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Nabilone is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Nabilone.Approved
EnasidenibThe metabolism of Enasidenib can be decreased when combined with Nabilone.Approved, Investigational
EnfluraneNabilone may increase the central nervous system depressant (CNS depressant) activities of Enflurane.Approved, Investigational, Vet Approved
EntacaponeNabilone may increase the central nervous system depressant (CNS depressant) activities of Entacapone.Approved, Investigational
EnzalutamideThe metabolism of Enzalutamide can be decreased when combined with Nabilone.Approved
EpanololNabilone may increase the tachycardic activities of Epanolol.Experimental
EphedrineNabilone may increase the tachycardic activities of Ephedrine.Approved
EpinephrineNabilone may increase the tachycardic activities of Epinephrine.Approved, Vet Approved
EplerenoneThe risk or severity of adverse effects can be increased when Nabilone is combined with Eplerenone.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Nabilone.Approved
EprosartanThe risk or severity of adverse effects can be increased when Nabilone is combined with Eprosartan.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Nabilone.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Nabilone.Approved
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Nabilone.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when Nabilone is combined with Escitalopram.Approved, Investigational
EsmololThe risk or severity of adverse effects can be increased when Nabilone is combined with Esmolol.Approved
EstazolamNabilone may increase the central nervous system depressant (CNS depressant) activities of Estazolam.Approved, Illicit
EstradiolThe metabolism of Estradiol can be decreased when combined with Nabilone.Approved, Investigational, Vet Approved
Estradiol acetateThe metabolism of Estradiol acetate can be decreased when combined with Nabilone.Approved, Investigational, Vet Approved
Estradiol benzoateThe metabolism of Estradiol benzoate can be decreased when combined with Nabilone.Approved, Investigational, Vet Approved
Estradiol cypionateThe metabolism of Estradiol cypionate can be decreased when combined with Nabilone.Approved, Investigational, Vet Approved
Estradiol dienanthateThe metabolism of Estradiol dienanthate can be decreased when combined with Nabilone.Approved, Investigational, Vet Approved
Estradiol valerateThe metabolism of Estradiol valerate can be decreased when combined with Nabilone.Approved, Investigational, Vet Approved
EstroneThe metabolism of Estrone can be decreased when combined with Nabilone.Approved
EszopicloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Eszopiclone.Approved, Investigational
Etacrynic acidThe risk or severity of adverse effects can be increased when Nabilone is combined with Etacrynic acid.Approved, Investigational
EtanautineEtanautine may increase the tachycardic activities of Nabilone.Experimental
EthanolNabilone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolNabilone may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.Approved, Illicit, Withdrawn
EthopropazineEthopropazine may increase the tachycardic activities of Nabilone.Approved
EthosuximideNabilone may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.Approved
EthotoinNabilone may increase the central nervous system depressant (CNS depressant) activities of Ethotoin.Approved
Ethyl carbamateNabilone may increase the central nervous system depressant (CNS depressant) activities of Ethyl carbamate.Withdrawn
Ethyl chlorideNabilone may increase the central nervous system depressant (CNS depressant) activities of Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateNabilone may increase the central nervous system depressant (CNS depressant) activities of Ethyl loflazepate.Approved, Illicit
EthylmorphineNabilone may increase the central nervous system depressant (CNS depressant) activities of Ethylmorphine.Approved, Illicit
EtidocaineNabilone may increase the central nervous system depressant (CNS depressant) activities of Etidocaine.Approved
EtifoxineNabilone may increase the central nervous system depressant (CNS depressant) activities of Etifoxine.Investigational, Withdrawn
EtilefrineNabilone may increase the tachycardic activities of Etilefrine.Withdrawn
EtizolamNabilone may increase the central nervous system depressant (CNS depressant) activities of Etizolam.Approved
EtodolacThe metabolism of Etodolac can be decreased when combined with Nabilone.Approved, Investigational, Vet Approved
EtomidateNabilone may increase the central nervous system depressant (CNS depressant) activities of Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Nabilone is combined with Etoperidone.Withdrawn
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Nabilone.Approved, Investigational
EtorphineNabilone may increase the central nervous system depressant (CNS depressant) activities of Etorphine.Illicit, Vet Approved
EtravirineThe metabolism of Etravirine can be decreased when combined with Nabilone.Approved
EtybenzatropineEtybenzatropine may increase the tachycardic activities of Nabilone.Experimental
EzogabineNabilone may increase the central nervous system depressant (CNS depressant) activities of Ezogabine.Approved, Investigational
FelbamateNabilone may increase the central nervous system depressant (CNS depressant) activities of Felbamate.Approved
FelodipineThe risk or severity of adverse effects can be increased when Nabilone is combined with Felodipine.Approved, Investigational
FencamfamineNabilone may increase the central nervous system depressant (CNS depressant) activities of Fencamfamine.Approved, Illicit, Withdrawn
FenoldopamThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Nabilone.Approved
FenoterolNabilone may increase the tachycardic activities of Fenoterol.Approved, Investigational
FenozoloneNabilone may increase the tachycardic activities of Fenozolone.Experimental
FentanylNabilone may increase the central nervous system depressant (CNS depressant) activities of Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineFesoterodine may increase the tachycardic activities of Nabilone.Approved
FexofenadineNabilone may increase the central nervous system depressant (CNS depressant) activities of Fexofenadine.Approved, Investigational
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Nabilone.Approved, Investigational
FlavoxateFlavoxate may increase the tachycardic activities of Nabilone.Approved
FlibanserinNabilone may increase the central nervous system depressant (CNS depressant) activities of Flibanserin.Approved, Investigational
FluanisoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Fluanisone.Experimental
FludiazepamNabilone may increase the central nervous system depressant (CNS depressant) activities of Fludiazepam.Approved, Illicit
FlunarizineNabilone may increase the central nervous system depressant (CNS depressant) activities of Flunarizine.Approved
FlunitrazepamNabilone may increase the central nervous system depressant (CNS depressant) activities of Flunitrazepam.Approved, Illicit
FluorouracilThe metabolism of Fluorouracil can be decreased when combined with Nabilone.Approved
FluoxetineThe risk or severity of adverse effects can be increased when Nabilone is combined with Fluoxetine.Approved, Vet Approved
FlupentixolNabilone may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.Approved, Investigational, Withdrawn
FluphenazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.Approved
FlurazepamNabilone may increase the central nervous system depressant (CNS depressant) activities of Flurazepam.Approved, Illicit, Investigational
FlurbiprofenThe metabolism of Flurbiprofen can be decreased when combined with Nabilone.Approved, Investigational
FluspirileneNabilone may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene.Approved, Investigational
Fluticasone propionateNabilone may increase the central nervous system depressant (CNS depressant) activities of Fluticasone propionate.Approved
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Nabilone.Approved
FluvoxamineNabilone may increase the central nervous system depressant (CNS depressant) activities of Fluvoxamine.Approved, Investigational
FormoterolThe metabolism of Formoterol can be decreased when combined with Nabilone.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Nabilone is combined with Fosinopril.Approved
FosphenytoinNabilone may increase the central nervous system depressant (CNS depressant) activities of Fosphenytoin.Approved, Investigational
FospropofolNabilone may increase the central nervous system depressant (CNS depressant) activities of Fospropofol.Approved, Illicit, Investigational
FurosemideThe risk or severity of adverse effects can be increased when Nabilone is combined with Furosemide.Approved, Vet Approved
GabapentinNabilone may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.Approved, Investigational
Gabapentin EnacarbilNabilone may increase the central nervous system depressant (CNS depressant) activities of Gabapentin Enacarbil.Approved, Investigational
GallamineGallamine may increase the tachycardic activities of Nabilone.Experimental
Gallamine TriethiodideGallamine Triethiodide may increase the tachycardic activities of Nabilone.Approved
Gamma Hydroxybutyric AcidNabilone may increase the central nervous system depressant (CNS depressant) activities of Gamma Hydroxybutyric Acid.Approved, Illicit, Investigational
GavestinelThe metabolism of Gavestinel can be decreased when combined with Nabilone.Investigational
GepironeNabilone may increase the central nervous system depressant (CNS depressant) activities of Gepirone.Investigational
GliclazideThe metabolism of Gliclazide can be decreased when combined with Nabilone.Approved
GlimepirideThe metabolism of Glimepiride can be decreased when combined with Nabilone.Approved
GlipizideThe metabolism of Glipizide can be decreased when combined with Nabilone.Approved, Investigational
GlutethimideNabilone may increase the central nervous system depressant (CNS depressant) activities of Glutethimide.Approved, Illicit
GlyburideThe metabolism of Glyburide can be decreased when combined with Nabilone.Approved
GlycopyrroniumGlycopyrronium may increase the tachycardic activities of Nabilone.Approved, Investigational, Vet Approved
GuanfacineNabilone may increase the central nervous system depressant (CNS depressant) activities of Guanfacine.Approved, Investigational
HalazepamNabilone may increase the central nervous system depressant (CNS depressant) activities of Halazepam.Approved, Illicit, Withdrawn
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Nabilone.Approved
HaloperidolNabilone may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.Approved
HalothaneNabilone may increase the central nervous system depressant (CNS depressant) activities of Halothane.Approved, Vet Approved
HeroinNabilone may increase the central nervous system depressant (CNS depressant) activities of Heroin.Approved, Illicit, Investigational
HexobarbitalNabilone may increase the central nervous system depressant (CNS depressant) activities of Hexobarbital.Approved
HistamineThe metabolism of Histamine can be decreased when combined with Nabilone.Approved, Investigational
HomatropineHomatropine may increase the tachycardic activities of Nabilone.Approved
HydralazineThe risk or severity of adverse effects can be increased when Nabilone is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Nabilone is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Nabilone.Approved, Investigational
HydromorphoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone.Approved, Illicit
HydroxyamphetamineNabilone may increase the tachycardic activities of Hydroxyamphetamine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Nabilone.Approved
HyoscyamineHyoscyamine may increase the tachycardic activities of Nabilone.Approved
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Nabilone.Approved
IbuprofenThe metabolism of Ibuprofen can be decreased when combined with Nabilone.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Nabilone.Approved
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Nabilone.Approved
IloperidoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Iloperidone.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Nabilone.Approved, Investigational
ImatinibThe metabolism of Imatinib can be decreased when combined with Nabilone.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Nabilone.Investigational
ImipramineNabilone may increase the central nervous system depressant (CNS depressant) activities of Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Nabilone is combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Nabilone is combined with Indapamide.Approved
IndiplonNabilone may increase the central nervous system depressant (CNS depressant) activities of Indiplon.Investigational
IndisulamThe metabolism of Indisulam can be decreased when combined with Nabilone.Investigational
IndomethacinThe metabolism of Indomethacin can be decreased when combined with Nabilone.Approved, Investigational
IndoraminThe risk or severity of adverse effects can be increased when Indoramin is combined with Nabilone.Withdrawn
IpratropiumIpratropium bromide may increase the tachycardic activities of Nabilone.Approved
IrbesartanThe risk or severity of adverse effects can be increased when Nabilone is combined with Irbesartan.Approved, Investigational
IsocarboxazidThe therapeutic efficacy of Nabilone can be increased when used in combination with Isocarboxazid.Approved
IsofluraneNabilone may increase the central nervous system depressant (CNS depressant) activities of Isoflurane.Approved, Vet Approved
IsoprenalineNabilone may increase the tachycardic activities of Isoprenaline.Approved, Investigational
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Nabilone is combined with Isosorbide Dinitrate.Approved, Investigational
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Nabilone is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Nabilone is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Nabilone is combined with Isradipine.Approved, Investigational
IxazomibThe metabolism of Ixazomib can be decreased when combined with Nabilone.Approved, Investigational
KetamineNabilone may increase the central nervous system depressant (CNS depressant) activities of Ketamine.Approved, Vet Approved
KetazolamNabilone may increase the central nervous system depressant (CNS depressant) activities of Ketazolam.Approved
KetobemidoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Ketobemidone.Approved, Investigational
KetoprofenThe metabolism of Ketoprofen can be decreased when combined with Nabilone.Approved, Vet Approved
LabetalolThe risk or severity of adverse effects can be increased when Nabilone is combined with Labetalol.Approved
LacidipineNabilone may increase the hypotensive activities of Lacidipine.Approved, Investigational
LamotrigineNabilone may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.Approved, Investigational
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Nabilone.Approved, Investigational
LapatinibThe metabolism of Lapatinib can be decreased when combined with Nabilone.Approved, Investigational
LeflunomideThe metabolism of Leflunomide can be decreased when combined with Nabilone.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Nabilone.Approved, Investigational
LesinuradThe metabolism of Lesinurad can be decreased when combined with Nabilone.Approved, Investigational
LevetiracetamNabilone may increase the central nervous system depressant (CNS depressant) activities of Levetiracetam.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Nabilone is combined with Levobunolol.Approved
LevobupivacaineNabilone may increase the central nervous system depressant (CNS depressant) activities of Levobupivacaine.Approved, Investigational
LevocabastineNabilone may increase the central nervous system depressant (CNS depressant) activities of Levocabastine.Approved, Investigational
LevocetirizineNabilone may increase the central nervous system depressant (CNS depressant) activities of Levocetirizine.Approved
LevodopaNabilone may increase the orthostatic hypotensive activities of Levodopa.Approved
Levomethadyl AcetateNabilone may increase the central nervous system depressant (CNS depressant) activities of Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Nabilone is combined with Levomilnacipran.Approved, Investigational
LevorphanolNabilone may increase the central nervous system depressant (CNS depressant) activities of Levorphanol.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Nabilone.Approved, Investigational
LicofeloneThe metabolism of Licofelone can be decreased when combined with Nabilone.Investigational
LidocaineNabilone may increase the central nervous system depressant (CNS depressant) activities of Lidocaine.Approved, Vet Approved
LisinoprilThe risk or severity of adverse effects can be increased when Nabilone is combined with Lisinopril.Approved, Investigational
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Nabilone.Approved, Investigational
Lithium cationNabilone may increase the central nervous system depressant (CNS depressant) activities of Lithium.Experimental
LofentanilNabilone may increase the central nervous system depressant (CNS depressant) activities of Lofentanil.Illicit
LofexidineThe therapeutic efficacy of Nabilone can be increased when used in combination with Lofexidine.Approved, Investigational
LoperamideThe metabolism of Loperamide can be decreased when combined with Nabilone.Approved
LoprazolamNabilone may increase the central nervous system depressant (CNS depressant) activities of Loprazolam.Experimental
LoratadineNabilone may increase the central nervous system depressant (CNS depressant) activities of Loratadine.Approved, Investigational
LorazepamNabilone may increase the central nervous system depressant (CNS depressant) activities of Lorazepam.Approved
LormetazepamNabilone may increase the central nervous system depressant (CNS depressant) activities of Lormetazepam.Approved
LornoxicamThe metabolism of Lornoxicam can be decreased when combined with Nabilone.Approved, Investigational
LorpiprazoleThe serum concentration of Nabilone can be increased when it is combined with Lorpiprazole.Approved
LosartanThe risk or severity of adverse effects can be increased when Nabilone is combined with Losartan.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Nabilone.Approved, Investigational
LoxapineNabilone may increase the central nervous system depressant (CNS depressant) activities of Loxapine.Approved
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Nabilone.Approved, Investigational
LurasidoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Nabilone.Illicit, Investigational, Withdrawn
Magnesium sulfateThe therapeutic efficacy of Nabilone can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
MannitolThe risk or severity of adverse effects can be increased when Nabilone is combined with Mannitol.Approved, Investigational
MaprotilineNabilone may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.Approved, Investigational
MazaticolMazaticol may increase the tachycardic activities of Nabilone.Experimental
MebicarNabilone may increase the central nervous system depressant (CNS depressant) activities of Mebicar.Experimental
MecamylamineMecamylamine may increase the tachycardic activities of Nabilone.Approved, Investigational
MeclizineNabilone may increase the central nervous system depressant (CNS depressant) activities of Meclizine.Approved
MedazepamNabilone may increase the central nervous system depressant (CNS depressant) activities of Medazepam.Experimental
MedetomidineNabilone may increase the central nervous system depressant (CNS depressant) activities of Medetomidine.Vet Approved
Medical CannabisThe metabolism of Medical Cannabis can be decreased when combined with Nabilone.Experimental, Investigational
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Nabilone.Approved
MefenorexNabilone may increase the tachycardic activities of Mefenorex.Experimental
MelatoninNabilone may increase the central nervous system depressant (CNS depressant) activities of Melatonin.Approved, Nutraceutical, Vet Approved
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Nabilone.Approved, Vet Approved
MelperoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Melperone.Approved, Investigational
MephentermineNabilone may increase the tachycardic activities of Mephentermine.Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Nabilone.Investigational, Withdrawn
MepivacaineNabilone may increase the central nervous system depressant (CNS depressant) activities of Mepivacaine.Approved, Vet Approved
MeprobamateNabilone may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.Approved, Illicit
MeptazinolNabilone may increase the central nervous system depressant (CNS depressant) activities of Meptazinol.Experimental
MesoridazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Mesoridazine.Approved, Investigational
MestranolThe metabolism of Mestranol can be decreased when combined with Nabilone.Approved
MetaraminolNabilone may increase the tachycardic activities of Metaraminol.Approved, Investigational
MetaxaloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Metaxalone.Approved
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Nabilone.Experimental
MethadoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved
Methadyl AcetateNabilone may increase the central nervous system depressant (CNS depressant) activities of Methadyl Acetate.Approved, Illicit
MethamphetamineNabilone may increase the tachycardic activities of Methamphetamine.Approved, Illicit
MethanthelineMethantheline may increase the tachycardic activities of Nabilone.Approved, Investigational
MethapyrileneNabilone may increase the central nervous system depressant (CNS depressant) activities of Methapyrilene.Withdrawn
MethaqualoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Methaqualone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Nabilone is combined with Methazolamide.Approved
MethocarbamolNabilone may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.Approved, Vet Approved
MethohexitalNabilone may increase the central nervous system depressant (CNS depressant) activities of Methohexital.Approved
MethotrimeprazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxamineNabilone may increase the tachycardic activities of Methoxamine.Approved, Investigational
MethoxyfluraneNabilone may increase the central nervous system depressant (CNS depressant) activities of Methoxyflurane.Approved, Investigational, Vet Approved
MethscopolamineMethscopolamine may increase the tachycardic activities of Nabilone.Approved
MethsuximideNabilone may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Nabilone is combined with Methyclothiazide.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Nabilone is combined with Methyldopa.Approved
MethylecgonineNabilone may increase the central nervous system depressant (CNS depressant) activities of Methylecgonine.Experimental
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Nabilone.Approved
MethylphenobarbitalNabilone may increase the central nervous system depressant (CNS depressant) activities of Methylphenobarbital.Approved
Methylscopolamine bromideMethylscopolamine bromide may increase the tachycardic activities of Nabilone.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Nabilone.Approved
MetipranololThe risk or severity of adverse effects can be increased when Nabilone is combined with Metipranolol.Approved
MetixeneMetixene may increase the tachycardic activities of Nabilone.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Nabilone is combined with Metolazone.Approved
MetoprololThe risk or severity of adverse effects can be increased when Nabilone is combined with Metoprolol.Approved, Investigational
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Nabilone.Approved
MetyrosineNabilone may increase the sedative activities of Metyrosine.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Nabilone.Experimental
MidazolamNabilone may increase the central nervous system depressant (CNS depressant) activities of Midazolam.Approved, Illicit
MidodrineNabilone may increase the tachycardic activities of Midodrine.Approved
MilnacipranThe risk or severity of adverse effects can be increased when Nabilone is combined with Milnacipran.Approved, Investigational
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Nabilone.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Nabilone is combined with Minoxidil.Approved, Investigational
MirtazapineNabilone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Nabilone.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Nabilone is combined with Moexipril.Approved
MolindoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Molindone.Approved
MontelukastThe metabolism of Montelukast can be decreased when combined with Nabilone.Approved
MorphineNabilone may increase the central nervous system depressant (CNS depressant) activities of Morphine.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Moxonidine is combined with Nabilone.Approved, Investigational
MuraglitazarThe metabolism of Muraglitazar can be decreased when combined with Nabilone.Investigational
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Nabilone.Approved, Investigational
NabiximolsThe metabolism of Nabiximols can be decreased when combined with Nabilone.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Nabilone is combined with Nadolol.Approved
NalbuphineNabilone may increase the central nervous system depressant (CNS depressant) activities of Nalbuphine.Approved
NaloxoneThe metabolism of Naloxone can be decreased when combined with Nabilone.Approved, Vet Approved
NaproxenThe metabolism of Naproxen can be decreased when combined with Nabilone.Approved, Vet Approved
NateglinideThe metabolism of Nateglinide can be decreased when combined with Nabilone.Approved, Investigational
NebivololThe risk or severity of adverse effects can be increased when Nabilone is combined with Nebivolol.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Nabilone is combined with Nefazodone.Approved, Withdrawn
NesiritideThe risk or severity of adverse effects can be increased when Nabilone is combined with Nesiritide.Approved, Investigational
NetupitantThe metabolism of Netupitant can be decreased when combined with Nabilone.Approved, Investigational
NevirapineThe metabolism of Nevirapine can be decreased when combined with Nabilone.Approved
NicardipineThe risk or severity of adverse effects can be increased when Nabilone is combined with Nicardipine.Approved, Investigational
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Nabilone.Approved, Investigational
NiclosamideThe metabolism of Niclosamide can be decreased when combined with Nabilone.Approved, Investigational, Vet Approved
NicorandilNicorandil may increase the hypotensive activities of Nabilone.Approved, Investigational
NicotineThe metabolism of Nicotine can be decreased when combined with Nabilone.Approved
NifedipineThe risk or severity of adverse effects can be increased when Nabilone is combined with Nifedipine.Approved
NilvadipineThe risk or severity of adverse effects can be increased when Nabilone is combined with Nilvadipine.Approved, Investigational
NimodipineThe risk or severity of adverse effects can be increased when Nabilone is combined with Nimodipine.Approved, Investigational
NisoldipineThe risk or severity of adverse effects can be increased when Nabilone is combined with Nisoldipine.Approved
NitrazepamNabilone may increase the central nervous system depressant (CNS depressant) activities of Nitrazepam.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Nabilone is combined with Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nabilone is combined with Nitric Oxide.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nabilone is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nabilone is combined with Nitroprusside.Approved, Investigational
Nitrous acidThe risk or severity of adverse effects can be increased when Nabilone is combined with Nitrous acid.Approved, Investigational
Nitrous oxideNabilone may increase the central nervous system depressant (CNS depressant) activities of Nitrous oxide.Approved, Vet Approved
NordazepamNabilone may increase the central nervous system depressant (CNS depressant) activities of Nordazepam.Approved
NorepinephrineNabilone may increase the tachycardic activities of Norepinephrine.Approved
NorfluraneNabilone may increase the central nervous system depressant (CNS depressant) activities of Norflurane.Approved, Investigational
NormethadoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Normethadone.Approved, Illicit
NortriptylineNabilone may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.Approved
NylidrinNabilone may increase the tachycardic activities of Nylidrin.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Nabilone is combined with Obinutuzumab.Approved, Investigational
OdanacatibThe metabolism of Odanacatib can be decreased when combined with Nabilone.Investigational
OlanzapineNabilone may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.Approved, Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Nabilone is combined with Olmesartan.Approved, Investigational
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Nabilone.Approved
OlopatadineNabilone may increase the central nervous system depressant (CNS depressant) activities of Olopatadine.Approved
OmbitasvirThe metabolism of Ombitasvir can be decreased when combined with Nabilone.Approved, Investigational
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Nabilone.Approved, Investigational, Vet Approved
OndansetronNabilone may increase the central nervous system depressant (CNS depressant) activities of Ondansetron.Approved
OpiumNabilone may increase the central nervous system depressant (CNS depressant) activities of Opium.Approved, Illicit
OrciprenalineNabilone may increase the tachycardic activities of Orciprenaline.Approved
OrphenadrineNabilone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantNabilone may increase the central nervous system depressant (CNS depressant) activities of Osanetant.Investigational
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Nabilone.Approved, Investigational
OtiloniumOtilonium may increase the tachycardic activities of Nabilone.Experimental, Investigational
OxaprozinThe metabolism of Oxaprozin can be decreased when combined with Nabilone.Approved
OxazepamNabilone may increase the central nervous system depressant (CNS depressant) activities of Oxazepam.Approved
OxitropiumOxitropium may increase the tachycardic activities of Nabilone.Investigational
OxprenololNabilone may increase the central nervous system depressant (CNS depressant) activities of Oxprenolol.Approved
OxybuprocaineNabilone may increase the central nervous system depressant (CNS depressant) activities of Oxybuprocaine.Approved, Investigational
OxybutyninOxybutynin may increase the tachycardic activities of Nabilone.Approved, Investigational
OxycodoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Oxycodone.Approved, Illicit, Investigational
OxymetazolineNabilone may increase the tachycardic activities of Oxymetazoline.Approved, Investigational
OxymorphoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumOxyphenonium may increase the tachycardic activities of Nabilone.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Nabilone is combined with Paclitaxel.Approved, Vet Approved
PaliperidoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.Approved
PancuroniumPancuronium may increase the tachycardic activities of Nabilone.Approved
PapaverineThe risk or severity of adverse effects can be increased when Nabilone is combined with Papaverine.Approved, Investigational
ParaldehydeNabilone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Nabilone.Approved
ParecoxibThe metabolism of Parecoxib can be decreased when combined with Nabilone.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Nabilone is combined with Paroxetine.Approved, Investigational
PazopanibThe metabolism of Pazopanib can be decreased when combined with Nabilone.Approved
PenbutololThe risk or severity of adverse effects can be increased when Nabilone is combined with Penbutolol.Approved, Investigational
PenfluridolNabilone may increase the central nervous system depressant (CNS depressant) activities of Penfluridol.Experimental
PentamidineThe metabolism of Pentamidine can be decreased when combined with Nabilone.Approved, Investigational
PentazocineNabilone may increase the central nervous system depressant (CNS depressant) activities of Pentazocine.Approved, Vet Approved
PentobarbitalNabilone may increase the central nervous system depressant (CNS depressant) activities of Pentobarbital.Approved, Investigational, Vet Approved
PentoliniumPentolinium may increase the tachycardic activities of Nabilone.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Nabilone.Approved
PerazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Perazine.Approved, Investigational
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Nabilone.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilThe risk or severity of adverse effects can be increased when Nabilone is combined with Perindopril.Approved
PerospironeNabilone may increase the central nervous system depressant (CNS depressant) activities of Perospirone.Approved
PerphenazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Perphenazine.Approved
PethidineNabilone may increase the central nervous system depressant (CNS depressant) activities of Pethidine.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Nabilone.Withdrawn
PhenazocineNabilone may increase the central nervous system depressant (CNS depressant) activities of Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Nabilone is combined with Phenelzine.Approved
PhenglutarimidePhenglutarimide may increase the tachycardic activities of Nabilone.Experimental
PhenibutNabilone may increase the central nervous system depressant (CNS depressant) activities of Phenibut.Experimental
PhenmetrazineNabilone may increase the tachycardic activities of Phenmetrazine.Approved, Illicit
PhenobarbitalNabilone may increase the central nervous system depressant (CNS depressant) activities of Phenobarbital.Approved, Investigational
PhenoperidineNabilone may increase the central nervous system depressant (CNS depressant) activities of Phenoperidine.Experimental
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Nabilone is combined with Phenoxybenzamine.Approved
PhenoxyethanolNabilone may increase the central nervous system depressant (CNS depressant) activities of Phenoxyethanol.Approved
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Nabilone.Approved, Investigational
PhentermineNabilone may increase the tachycardic activities of Phentermine.Approved, Illicit
PhentolamineThe risk or severity of adverse effects can be increased when Nabilone is combined with Phentolamine.Approved
PhenylbutazoneThe metabolism of Phenylbutazone can be decreased when combined with Nabilone.Approved, Vet Approved
PhenylephrineNabilone may increase the tachycardic activities of Phenylephrine.Approved
PhenylpropanolamineNabilone may increase the tachycardic activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinNabilone may increase the central nervous system depressant (CNS depressant) activities of Phenytoin.Approved, Vet Approved
PimozideNabilone may increase the central nervous system depressant (CNS depressant) activities of Pimozide.Approved
PindololThe risk or severity of adverse effects can be increased when Nabilone is combined with Pindolol.Approved, Investigational
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Nabilone.Approved, Investigational
PipamperoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Pipamperone.Approved, Investigational
PipecuroniumPipecuronium may increase the tachycardic activities of Nabilone.Approved
PiperaquineThe metabolism of Piperaquine can be decreased when combined with Nabilone.Approved, Investigational
PipotiazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Pipotiazine.Approved, Investigational
PirenzepinePirenzepine may increase the tachycardic activities of Nabilone.Approved
PiritramideNabilone may increase the central nervous system depressant (CNS depressant) activities of Piritramide.Approved, Investigational
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Nabilone.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Nabilone.Approved
PizotifenNabilone may increase the central nervous system depressant (CNS depressant) activities of Pizotifen.Approved
PomalidomideNabilone may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Nabilone.Approved, Investigational
PramipexoleNabilone may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineNabilone may increase the central nervous system depressant (CNS depressant) activities of Pramocaine.Approved
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Nabilone.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Nabilone.Approved
PrazepamNabilone may increase the central nervous system depressant (CNS depressant) activities of Prazepam.Approved, Illicit
PrazosinThe risk or severity of adverse effects can be increased when Nabilone is combined with Prazosin.Approved
PregabalinNabilone may increase the central nervous system depressant (CNS depressant) activities of Pregabalin.Approved, Illicit, Investigational
PrenalterolNabilone may increase the tachycardic activities of Prenalterol.Experimental
PrilocaineNabilone may increase the central nervous system depressant (CNS depressant) activities of Prilocaine.Approved
PrimidoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Primidone.Approved, Vet Approved
ProcaineNabilone may increase the central nervous system depressant (CNS depressant) activities of Procaine.Approved, Investigational, Vet Approved
ProcaterolNabilone may increase the tachycardic activities of Procaterol.Approved, Investigational
ProchlorperazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.Approved, Vet Approved
ProcyclidineProcyclidine may increase the tachycardic activities of Nabilone.Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Nabilone.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Nabilone.Approved
PromazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Promazine.Approved, Vet Approved
PromethazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Promethazine.Approved, Investigational
PropanididNabilone may increase the central nervous system depressant (CNS depressant) activities of Propanidid.Experimental
PropanthelinePropantheline may increase the tachycardic activities of Nabilone.Approved
ProparacaineNabilone may increase the central nervous system depressant (CNS depressant) activities of Proparacaine.Approved, Vet Approved
PropiverinePropiverine may increase the tachycardic activities of Nabilone.Approved, Investigational
PropofolNabilone may increase the central nervous system depressant (CNS depressant) activities of Propofol.Approved, Investigational, Vet Approved
PropoxycaineNabilone may increase the central nervous system depressant (CNS depressant) activities of Propoxycaine.Approved
PropranololThe risk or severity of adverse effects can be increased when Nabilone is combined with Propranolol.Approved, Investigational
ProtriptylineNabilone may increase the central nervous system depressant (CNS depressant) activities of Protriptyline.Approved
ProxibarbalNabilone may increase the central nervous system depressant (CNS depressant) activities of Proxibarbal.Experimental
PSD502Nabilone may increase the central nervous system depressant (CNS depressant) activities of PSD502.Investigational
PseudoephedrineNabilone may increase the tachycardic activities of Pseudoephedrine.Approved
QuazepamNabilone may increase the central nervous system depressant (CNS depressant) activities of Quazepam.Approved, Illicit
QuetiapineNabilone may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Nabilone is combined with Quinapril.Approved, Investigational
QuinidineQuinidine may increase the tachycardic activities of Nabilone.Approved, Investigational
QuinineThe metabolism of Quinine can be decreased when combined with Nabilone.Approved
QuinisocaineNabilone may increase the central nervous system depressant (CNS depressant) activities of Quinisocaine.Experimental
RacepinephrineNabilone may increase the tachycardic activities of Racepinephrine.Approved
RacloprideNabilone may increase the central nervous system depressant (CNS depressant) activities of Raclopride.Investigational
RamelteonNabilone may increase the central nervous system depressant (CNS depressant) activities of Ramelteon.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Nabilone is combined with Ramipril.Approved
RasagilineThe risk or severity of adverse effects can be increased when Nabilone is combined with Rasagiline.Approved
RemifentanilNabilone may increase the central nervous system depressant (CNS depressant) activities of Remifentanil.Approved
RemoxiprideNabilone may increase the central nervous system depressant (CNS depressant) activities of Remoxipride.Approved, Withdrawn
RepaglinideThe metabolism of Repaglinide can be decreased when combined with Nabilone.Approved, Investigational
ReserpineNabilone may increase the central nervous system depressant (CNS depressant) activities of Reserpine.Approved, Investigational
RifampicinThe metabolism of Rifampicin can be decreased when combined with Nabilone.Approved
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Nabilone.Approved
RiociguatThe risk or severity of adverse effects can be increased when Nabilone is combined with Riociguat.Approved
RisperidoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Risperidone.Approved, Investigational
RitanserinNabilone may increase the central nervous system depressant (CNS depressant) activities of Ritanserin.Investigational
RitodrineNabilone may increase the tachycardic activities of Ritodrine.Approved, Investigational
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Nabilone.Approved, Investigational, Withdrawn
RomifidineNabilone may increase the central nervous system depressant (CNS depressant) activities of Romifidine.Vet Approved
RopiniroleNabilone may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineNabilone may increase the central nervous system depressant (CNS depressant) activities of Ropivacaine.Approved
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Nabilone.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Nabilone.Approved
RotigotineNabilone may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Nabilone.Approved
RupatadineThe metabolism of Rupatadine can be decreased when combined with Nabilone.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Nabilone is combined with Sacubitril.Approved
Salicylic acidThe metabolism of Salicylic acid can be decreased when combined with Nabilone.Approved, Investigational, Vet Approved
ScopolamineNabilone may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.Approved, Investigational
SecobarbitalNabilone may increase the central nervous system depressant (CNS depressant) activities of Secobarbital.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Nabilone is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagThe metabolism of Selexipag can be decreased when combined with Nabilone.Approved
SepranoloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Sepranolone.Investigational
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Nabilone.Approved
SertindoleNabilone may increase the central nervous system depressant (CNS depressant) activities of Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Nabilone is combined with Sertraline.Approved
SevofluraneNabilone may increase the central nervous system depressant (CNS depressant) activities of Sevoflurane.Approved, Vet Approved
SildenafilThe metabolism of Sildenafil can be decreased when combined with Nabilone.Approved, Investigational
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Nabilone.Approved
SitagliptinThe metabolism of Sitagliptin can be decreased when combined with Nabilone.Approved, Investigational
SitaxentanThe metabolism of Sitaxentan can be decreased when combined with Nabilone.Approved, Investigational, Withdrawn
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Nabilone.Approved
SolifenacinSolifenacin may increase the tachycardic activities of Nabilone.Approved
SorafenibThe metabolism of Sorafenib can be decreased when combined with Nabilone.Approved, Investigational
SotalolThe risk or severity of adverse effects can be increased when Nabilone is combined with Sotalol.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Nabilone is combined with Spironolactone.Approved
StiripentolNabilone may increase the central nervous system depressant (CNS depressant) activities of Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Nabilone is combined with Streptokinase.Approved, Investigational
SufentanilNabilone may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.Approved, Investigational
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Nabilone.Approved, Investigational, Vet Approved
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Nabilone.Approved
SulfamoxoleThe metabolism of Sulfamoxole can be decreased when combined with Nabilone.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Nabilone.Approved
SulfisoxazoleThe metabolism of Sulfisoxazole can be decreased when combined with Nabilone.Approved, Vet Approved
SulpirideNabilone may increase the central nervous system depressant (CNS depressant) activities of Sulpiride.Approved, Investigational
SultoprideNabilone may increase the central nervous system depressant (CNS depressant) activities of Sultopride.Experimental
SuprofenThe metabolism of Suprofen can be decreased when combined with Nabilone.Approved, Withdrawn
SuvorexantNabilone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
SynephrineNabilone may increase the tachycardic activities of Synephrine.Experimental
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Nabilone.Approved
TamsulosinThe risk or severity of adverse effects can be increased when Nabilone is combined with Tamsulosin.Approved, Investigational
TandospironeNabilone may increase the central nervous system depressant (CNS depressant) activities of Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Nabilone.Approved
TasimelteonNabilone may increase the central nervous system depressant (CNS depressant) activities of Tasimelteon.Approved, Investigational
TazaroteneThe metabolism of Tazarotene can be decreased when combined with Nabilone.Approved, Investigational
TelmisartanThe risk or severity of adverse effects can be increased when Nabilone is combined with Telmisartan.Approved, Investigational
TemazepamNabilone may increase the central nervous system depressant (CNS depressant) activities of Temazepam.Approved, Investigational
TenoxicamThe metabolism of Tenoxicam can be decreased when combined with Nabilone.Approved
TerazosinThe risk or severity of adverse effects can be increased when Nabilone is combined with Terazosin.Approved
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Nabilone.Approved, Investigational, Vet Approved
TerbutalineNabilone may increase the tachycardic activities of Terbutaline.Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Nabilone.Approved, Withdrawn
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Nabilone.Experimental
TestosteroneThe metabolism of Testosterone can be decreased when combined with Nabilone.Approved, Investigational
Testosterone cypionateThe metabolism of Testosterone cypionate can be decreased when combined with Nabilone.Approved
Testosterone enanthateThe metabolism of Testosterone enanthate can be decreased when combined with Nabilone.Approved
Testosterone undecanoateThe metabolism of Testosterone undecanoate can be decreased when combined with Nabilone.Approved, Investigational
TetrabenazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Tetrabenazine.Approved, Investigational
TetracaineNabilone may increase the central nervous system depressant (CNS depressant) activities of Tetracaine.Approved, Vet Approved
TetrahydropalmatineNabilone may increase the central nervous system depressant (CNS depressant) activities of Tetrahydropalmatine.Investigational
TetrodotoxinNabilone may increase the central nervous system depressant (CNS depressant) activities of Tetrodotoxin.Investigational
TetryzolineNabilone may increase the tachycardic activities of Tetryzoline.Approved
ThalidomideNabilone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Theophylline can be decreased when combined with Nabilone.Approved
ThiamylalNabilone may increase the central nervous system depressant (CNS depressant) activities of Thiamylal.Approved, Vet Approved
ThiopentalNabilone may increase the central nervous system depressant (CNS depressant) activities of Thiopental.Approved, Vet Approved
ThioridazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Thioridazine.Approved, Withdrawn
ThiothixeneNabilone may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.Approved
TiagabineNabilone may increase the central nervous system depressant (CNS depressant) activities of Tiagabine.Approved, Investigational
TiaprideNabilone may increase the central nervous system depressant (CNS depressant) activities of Tiapride.Approved, Investigational
TiletamineNabilone may increase the central nervous system depressant (CNS depressant) activities of Tiletamine.Vet Approved
TilidineNabilone may increase the central nervous system depressant (CNS depressant) activities of Tilidine.Experimental
TimololThe risk or severity of adverse effects can be increased when Nabilone is combined with Timolol.Approved
TiotropiumTiotropium may increase the tachycardic activities of Nabilone.Approved
TizanidineNabilone may increase the central nervous system depressant (CNS depressant) activities of Tizanidine.Approved, Investigational
TolazolineThe risk or severity of adverse effects can be increased when Nabilone is combined with Tolazoline.Approved, Vet Approved
TolbutamideThe metabolism of Tolbutamide can be decreased when combined with Nabilone.Approved, Investigational
TolcaponeNabilone may increase the central nervous system depressant (CNS depressant) activities of Tolcapone.Approved, Withdrawn
TolterodineTolterodine may increase the tachycardic activities of Nabilone.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Nabilone.Approved
TopiramateNabilone may increase the central nervous system depressant (CNS depressant) activities of Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Nabilone is combined with Torasemide.Approved
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Nabilone.Approved, Investigational
TramadolNabilone may increase the central nervous system depressant (CNS depressant) activities of Tramadol.Approved, Investigational
TramazolineNabilone may increase the tachycardic activities of Tramazoline.Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Nabilone is combined with Trandolapril.Approved
TranylcypromineNabilone may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.Approved, Investigational
TrazodoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Trazodone.Approved, Investigational
TreprostinilThe metabolism of Treprostinil can be decreased when combined with Nabilone.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Nabilone is combined with Tretinoin.Approved, Investigational, Nutraceutical
TretoquinolNabilone may increase the tachycardic activities of Tretoquinol.Experimental
TriamtereneThe risk or severity of adverse effects can be increased when Nabilone is combined with Triamterene.Approved
TriazolamNabilone may increase the central nervous system depressant (CNS depressant) activities of Triazolam.Approved, Investigational
Tricaine methanesulfonateNabilone may increase the central nervous system depressant (CNS depressant) activities of Tricaine methanesulfonate.Vet Approved
TrichloroethyleneNabilone may increase the central nervous system depressant (CNS depressant) activities of Trichloroethylene.Approved
TrifluoperazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine.Approved, Investigational
TrifluperidolNabilone may increase the central nervous system depressant (CNS depressant) activities of Trifluperidol.Experimental
TriflupromazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.Approved, Vet Approved
TrihexyphenidylTrihexyphenidyl may increase the tachycardic activities of Nabilone.Approved
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Nabilone.Approved
TrimethaphanTrimethaphan may increase the tachycardic activities of Nabilone.Approved, Investigational
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Nabilone.Approved, Vet Approved
TrimipramineNabilone may increase the central nervous system depressant (CNS depressant) activities of Trimipramine.Approved
TriprolidineNabilone may increase the central nervous system depressant (CNS depressant) activities of Triprolidine.Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Nabilone.Investigational, Withdrawn
TropatepineTropatepine may increase the tachycardic activities of Nabilone.Experimental
TropicamideTropicamide may increase the tachycardic activities of Nabilone.Approved, Investigational
TrospiumTrospium may increase the tachycardic activities of Nabilone.Approved
TubocurarineTubocurarine may increase the tachycardic activities of Nabilone.Approved
TyramineNabilone may increase the tachycardic activities of Tyramine.Investigational, Nutraceutical
UmeclidiniumUmeclidinium may increase the tachycardic activities of Nabilone.Approved
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Nabilone.Approved, Investigational, Withdrawn
Valproic AcidNabilone may increase the central nervous system depressant (CNS depressant) activities of Valproic Acid.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Nabilone is combined with Valsartan.Approved, Investigational
VecuroniumVecuronium may increase the tachycardic activities of Nabilone.Approved
VelpatasvirThe metabolism of Velpatasvir can be decreased when combined with Nabilone.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Nabilone is combined with Venlafaxine.Approved
VeraliprideNabilone may increase the central nervous system depressant (CNS depressant) activities of Veralipride.Experimental
VerapamilThe risk or severity of adverse effects can be increased when Nabilone is combined with Verapamil.Approved
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Nabilone.Investigational
VigabatrinNabilone may increase the central nervous system depressant (CNS depressant) activities of Vigabatrin.Approved
Vinyl etherNabilone may increase the central nervous system depressant (CNS depressant) activities of Vinyl ether.Experimental
VismodegibThe metabolism of Vismodegib can be decreased when combined with Nabilone.Approved, Investigational
VoriconazoleThe metabolism of Voriconazole can be decreased when combined with Nabilone.Approved, Investigational
VortioxetineNabilone may increase the central nervous system depressant (CNS depressant) activities of Vortioxetine.Approved, Investigational
VoxilaprevirThe metabolism of Voxilaprevir can be decreased when combined with Nabilone.Approved, Investigational
WarfarinThe metabolism of Warfarin can be decreased when combined with Nabilone.Approved
XenonNabilone may increase the central nervous system depressant (CNS depressant) activities of Xenon.Experimental
XimelagatranThe metabolism of Ximelagatran can be decreased when combined with Nabilone.Approved, Investigational, Withdrawn
XylazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Xylazine.Vet Approved
YohimbineThe therapeutic efficacy of Nabilone can be decreased when used in combination with Yohimbine.Approved, Investigational, Vet Approved
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Nabilone.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Nabilone.Approved, Investigational
ZaleplonNabilone may increase the central nervous system depressant (CNS depressant) activities of Zaleplon.Approved, Illicit, Investigational
ZaltoprofenThe metabolism of Zaltoprofen can be decreased when combined with Nabilone.Approved, Investigational
ZiconotideNabilone may increase the central nervous system depressant (CNS depressant) activities of Ziconotide.Approved
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Nabilone.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Nabilone.Approved, Investigational, Withdrawn
ZimelidineThe risk or severity of adverse effects can be increased when Nabilone is combined with Zimelidine.Withdrawn
ZiprasidoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.Approved
ZolazepamNabilone may increase the central nervous system depressant (CNS depressant) activities of Zolazepam.Vet Approved
ZolpidemNabilone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideNabilone may increase the central nervous system depressant (CNS depressant) activities of Zonisamide.Approved, Investigational
ZopicloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Zopiclone.Approved
ZotepineNabilone may increase the central nervous system depressant (CNS depressant) activities of Zotepine.Approved, Investigational, Withdrawn
ZuclopenthixolNabilone may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Take without regard to meals. Avoid alcohol.

References

General References
  1. Cunningham D, Bradley CJ, Forrest GJ, Hutcheon AW, Adams L, Sneddon M, Harding M, Kerr DJ, Soukop M, Kaye SB: A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues. Eur J Cancer Clin Oncol. 1988 Apr;24(4):685-9. [PubMed:2838294]
  2. Niiranen A, Mattson K: Antiemetic efficacy of nabilone and dexamethasone: a randomized study of patients with lung cancer receiving chemotherapy. Am J Clin Oncol. 1987 Aug;10(4):325-9. [PubMed:3039831]
  3. Herman TS, Einhorn LH, Jones SE, Nagy C, Chester AB, Dean JC, Furnas B, Williams SD, Leigh SA, Dorr RT, Moon TE: Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med. 1979 Jun 7;300(23):1295-7. [PubMed:375088]
  4. Einhorn LH, Nagy C, Furnas B, Williams SD: Nabilone: an effective antiemetic in patients receiving cancer chemotherapy. J Clin Pharmacol. 1981 Aug-Sep;21(8-9 Suppl):64S-69S. [PubMed:6271844]
  5. Elsohly MA, Slade D: Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci. 2005 Dec 22;78(5):539-48. doi: 10.1016/j.lfs.2005.09.011. Epub 2005 Sep 30. [PubMed:16199061]
  6. Sharma P, Murthy P, Bharath MM: Chemistry, metabolism, and toxicology of cannabis: clinical implications. Iran J Psychiatry. 2012 Fall;7(4):149-56. [PubMed:23408483]
  7. Baron EP: Comprehensive Review of Medicinal Marijuana, Cannabinoids, and Therapeutic Implications in Medicine and Headache: What a Long Strange Trip It's Been .... Headache. 2015 Jun;55(6):885-916. doi: 10.1111/head.12570. Epub 2015 May 25. [PubMed:26015168]
  8. Kaur R, Ambwani SR, Singh S: Endocannabinoid System: A Multi-Facet Therapeutic Target. Curr Clin Pharmacol. 2016;11(2):110-7. [PubMed:27086601]
External Links
Human Metabolome Database
HMDB0014629
KEGG Drug
D05099
PubChem Compound
5284592
PubChem Substance
46505171
ChemSpider
4447641
BindingDB
50287941
ChEMBL
CHEMBL947
Therapeutic Targets Database
DAP000067
PharmGKB
PA164746998
Drugs.com
Drugs.com Drug Page
Wikipedia
Nabilone
ATC Codes
A04AD11 — Nabilone
AHFS Codes
  • 56:22.92 — Miscellaneous Antiemetics
FDA label
Download (94.9 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1, 2RecruitingBasic ScienceCannabis / Post Traumatic Stress Disorder (PTSD)1
1, 2RecruitingTreatmentObsessive-Compulsive Disorder (OCD)1
2CompletedPreventionProphylaxis against postoperative nausea and vomiting1
2CompletedTreatmentFibromyalgia1
2CompletedTreatmentMuscle Spasticity as a Result of Spinal Cord Injury1
2CompletedTreatmentPain, Neuropathic / Phantom Limb Pain (PLP)1
2Unknown StatusTreatmentPain / Sleeplessness1
2, 3Active Not RecruitingTreatmentAcute Agitation / Alzheimer's Disease (AD) / Obese experiencing rapid weight loss / Oxidative Stress / Pain1
2, 3CompletedTreatmentCannabis Dependence / Marijuana Dependence1
2, 3CompletedTreatmentSmoking, Marijuana1
2, 3RecruitingTreatmentAnorexic / Cachexia / Lung Cancer Non-Small Cell Cancer (NSCLC) / Weight Lose1
3Unknown StatusTreatmentDiabetic Neuropathies1
4CompletedTreatmentAntineoplastic Combined Chemotherapy Protocols / Peripheral Neuropathy1
4CompletedTreatmentDiabetic Neuropathies1
4CompletedTreatmentDisseminated Sclerosis1
4CompletedTreatmentDisseminated Sclerosis / Pain, Neuropathic1
4TerminatedTreatmentNausea and Vomiting1
Not AvailableCompletedNot AvailableFailed Back Surgery Syndrome1
Not AvailableCompletedTreatmentFibromyalgia / Sleep Initiation and Maintenance Disorders1
Not AvailableNot Yet RecruitingSupportive CareInflammatory Bowel Diseases (IBD)1

Pharmacoeconomics

Manufacturers
  • Meda pharmaceuticals inc
Packagers
  • Meda AB
  • Valeant Ltd.
Dosage forms
FormRouteStrength
CapsuleOral0.25 mg
CapsuleOral0.5 mg
CapsuleOral1 mg
CapsuleOral1 mg/1
CapsuleOral1.0 mg
Prices
Unit descriptionCostUnit
Cesamet 1 mg capsule13.99USD capsule
Cesamet 0.5 mg Capsule3.49USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP6.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000493 mg/mLALOGPS
logP7.5ALOGPS
logP6.36ChemAxon
logS-5.9ALOGPS
pKa (Strongest Acidic)9.33ChemAxon
pKa (Strongest Basic)-4.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area46.53 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity110.2 m3·mol-1ChemAxon
Polarizability44.91 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9954
Blood Brain Barrier+0.9575
Caco-2 permeable+0.7787
P-glycoprotein substrateSubstrate0.8103
P-glycoprotein inhibitor INon-inhibitor0.7926
P-glycoprotein inhibitor IIInhibitor0.6054
Renal organic cation transporterNon-inhibitor0.836
CYP450 2C9 substrateNon-substrate0.7385
CYP450 2D6 substrateNon-substrate0.8433
CYP450 3A4 substrateSubstrate0.6842
CYP450 1A2 substrateNon-inhibitor0.6601
CYP450 2C9 inhibitorNon-inhibitor0.714
CYP450 2D6 inhibitorNon-inhibitor0.9059
CYP450 2C19 inhibitorNon-inhibitor0.6521
CYP450 3A4 inhibitorNon-inhibitor0.8654
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7642
Ames testNon AMES toxic0.8337
CarcinogenicityNon-carcinogens0.8598
BiodegradationNot ready biodegradable0.9948
Rat acute toxicity2.5397 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9159
hERG inhibition (predictor II)Non-inhibitor0.7654
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as naphthopyranones. These are compounds containing a naphthopyran skeleton where a ring carbon bears a carboxylic acid group. Naphthtopyran is made up of the pyran ring fused to a naphthalene ring system.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Naphthopyrans
Sub Class
Naphthopyranones
Direct Parent
Naphthopyranones
Alternative Parents
2,2-dimethyl-1-benzopyrans / Alkyl aryl ethers / 1-hydroxy-4-unsubstituted benzenoids / 1-hydroxy-2-unsubstituted benzenoids / Cyclic ketones / Oxacyclic compounds / Organic oxides / Hydrocarbon derivatives
Substituents
Naphthopyranone / 2,2-dimethyl-1-benzopyran / Chromane / Benzopyran / 1-benzopyran / 1-hydroxy-4-unsubstituted benzenoid / 1-hydroxy-2-unsubstituted benzenoid / Alkyl aryl ether / Benzenoid / Ketone
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Partial agonist
General Function
Cannabinoid receptor activity
Specific Function
Heterotrimeric G protein-coupled receptor for endocannabinoid 2-arachidonoylglycerol mediating inhibition of adenylate cyclase. May function in inflammatory response, nociceptive transmission and b...
Gene Name
CNR2
Uniprot ID
P34972
Uniprot Name
Cannabinoid receptor 2
Molecular Weight
39680.275 Da
References
  1. Conti S, Costa B, Colleoni M, Parolaro D, Giagnoni G: Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat. Br J Pharmacol. 2002 Jan;135(1):181-7. [PubMed:11786493]
  2. Mendizabal VE, Adler-Graschinsky E: Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions. Br J Pharmacol. 2007 Jun;151(4):427-40. Epub 2007 Apr 23. [PubMed:17450170]
  3. Davis M, Maida V, Daeninck P, Pergolizzi J: The emerging role of cannabinoid neuromodulators in symptom management. Support Care Cancer. 2007 Jan;15(1):63-71. Epub 2006 Dec 1. [PubMed:17139494]
  4. Kraft B, Kress HG: [Cannabinoids and the immune system. Of men, mice and cells]. Schmerz. 2004 Jun;18(3):203-10. [PubMed:15221424]
  5. Darmani NA: The cannabinoid CB1 receptor antagonist SR 141716A reverses the antiemetic and motor depressant actions of WIN 55, 212-2. Eur J Pharmacol. 2001 Oct 26;430(1):49-58. [PubMed:11698062]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Partial agonist
General Function
Drug binding
Specific Function
Involved in cannabinoid-induced CNS effects. Acts by inhibiting adenylate cyclase. Could be a receptor for anandamide. Inhibits L-type Ca(2+) channel current. Isoform 2 and isoform 3 have altered l...
Gene Name
CNR1
Uniprot ID
P21554
Uniprot Name
Cannabinoid receptor 1
Molecular Weight
52857.365 Da
References
  1. Davis M, Maida V, Daeninck P, Pergolizzi J: The emerging role of cannabinoid neuromodulators in symptom management. Support Care Cancer. 2007 Jan;15(1):63-71. Epub 2006 Dec 1. [PubMed:17139494]
  2. Darmani NA: The cannabinoid CB1 receptor antagonist SR 141716A reverses the antiemetic and motor depressant actions of WIN 55, 212-2. Eur J Pharmacol. 2001 Oct 26;430(1):49-58. [PubMed:11698062]
  3. Hirst RA, Almond SL, Lambert DG: Characterisation of the rat cerebella CB1 receptor using SR141716A, a central cannabinoid receptor antagonist. Neurosci Lett. 1996 Dec 13;220(2):101-4. [PubMed:8981483]
  4. Pertwee RG: Cannabis and cannabinoids: pharmacology and rationale for clinical use. Forsch Komplementarmed. 1999 Oct;6 Suppl 3:12-5. [PubMed:10575283]
  5. Pertwee RG, Fernando SR: Evidence for the presence of cannabinoid CB1 receptors in mouse urinary bladder. Br J Pharmacol. 1996 Aug;118(8):2053-8. [PubMed:8864542]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da

Drug created on June 13, 2005 07:24 / Updated on July 13, 2018 01:00